All funds raised through the Cure Leukaemia Cycling Club will be invested in the national trials Acceleration Programme (TAP).
‘I thought it was curtains but then along came my miracle. 7 years later and I’m still taking the same dose. It continues to work.
They are remarkable little pills that I take. I got my life back.’
Mark Hill, London
The first patient treated on the ‘MAJIC’ clinical trial
‘Cure Leukaemia’s funding of the UK Trials Acceleration Programme (TAP) is a game-changer and increases the access for blood cancer patients to potentially transformative new therapies through the delivery of practice informing clinical trials which not only saves lives but also increases investment into this country’s economy. We have seen the urgent importance of clinical trials to combat the COVID-19 virus and we must not lose sight of the transformative role networks like TAP play in connecting blood cancer patients in the UK with critically important clinical trials.’
Sir John Bell
Regius Professor of Medicine at the University of Oxford & HM Government Vaccine Taskforce Advisor